Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis
作者： Laura J. Savage , Miriam Wittmann , Dennis McGonagle , Philip S. Helliwell
DOI: 10.1007/S40744-015-0010-2
关键词: Rheumatology 、 Psoriasis 、 Psoriatic arthritis 、 Disease 、 Internal medicine 、 Ustekinumab 、 Immunology 、 Interleukin 、 Inflammation 、 Pathogenesis 、 Medicine
摘要: Biologics have revolutionized the therapy of psoriatic disease spectrum. These new classes drugs also allow deeper insight into pathogenesis and highlight existence distinct "molecular" subgroups as evidenced by spectrum clinical response seen. Molecules associated with both interleukin (IL)-17 interferon (IFN)γ pathways important functions in inflammation, are targeted acting on p40 subunit shared IL-12 IL-23. family members upstream characterized production IFNγ IL-17 related molecules, including IL-17, IL-22, CCL20. We here summarize mode action studies inhibitor ustekinumab focus psoriasis arthritis.
core.ac.uk
springer.com
paperity.org参考文章(51)
W.P. Gulliver, G.B.E. Jemec, K.A. Baker, Experience with ustekinumab for the treatment of moderate to severe Hidradenitis suppurativa Journal of The European Academy of Dermatology and Venereology. ,vol. 26, pp. 911- 914 ,(2012) , 10.1111/J.1468-3083.2011.04123.X
Atsuyuki IGARASHI, Takeshi KATO, Mai KATO, Michael SONG, Hidemi NAKAGAWA, , Efficacy and safety of ustekinumab in Japanese patients with moderate‐to‐severe plaque‐type psoriasis: Long‐term results from a phase 2/3 clinical trial Journal of Dermatology. ,vol. 39, pp. 242- 252 ,(2012) , 10.1111/J.1346-8138.2011.01347.X
L. Guenther, C. Han, P. Szapary, B. Schenkel, Y. Poulin, M. Bourcier, J.P. Ortonne, H.L. Sofen, Impact of ustekinumab on health-related quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trials Journal of the European Academy of Dermatology and Venereology. ,vol. 25, pp. 851- 857 ,(2011) , 10.1111/J.1468-3083.2011.04082.X
KA1 Papp, CEM Griffiths, K Gordon, M Lebwohl, PO Szapary, Y Wasfi, D Chan, M‐C Hsu, V Ho, Pierre-Dominique Ghislain, B Strober, K Reich, PHOENIX 1, PHOENIX 2 and ACCEPT Investigators, Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. British Journal of Dermatology. ,vol. 168, pp. 844- 854 ,(2013) , 10.1111/BJD.12214
Ryuta Nishikomori, Takashi Usui, Chang-Yu Wu, Akio Morinobu, John J. O’Shea, Warren Strober, Activated STAT4 Has an Essential Role in Th1 Differentiation and Proliferation That Is Independent of Its Role in the Maintenance of IL-12Rβ2 Chain Expression and Signaling Journal of Immunology. ,vol. 169, pp. 4388- 4398 ,(2002) , 10.4049/JIMMUNOL.169.8.4388
Eiko Toichi, Gisela Torres, Thomas S. McCormick, Timothy Chang, Mary Ann Mascelli, Catharine L. Kauffman, Nancy Aria, Alice B. Gottlieb, Daniel E. Everitt, Bart Frederick, Charles E. Pendley, Kevin D. Cooper, An Anti-IL-12p40 Antibody Down-Regulates Type 1 Cytokines, Chemokines, and IL-12/IL-23 in Psoriasis Journal of Immunology. ,vol. 177, pp. 4917- 4926 ,(2006) , 10.4049/JIMMUNOL.177.7.4917
Ioana Cosgarea, Zdenka Lovric, Andreas Körber, Joachim Dissemond, Successful treatment of refractory pyoderma gangrenosum with ustekinumab only after excision of renal cell carcinoma International Wound Journal. ,vol. 13, pp. 1041- 1042 ,(2016) , 10.1111/IWJ.12377
J. Wohlrab, B. Kreft, Treatment of pityriasis rubra pilaris with ustekinumab. British Journal of Dermatology. ,vol. 163, pp. 655- 656 ,(2010) , 10.1111/J.1365-2133.2010.09855.X
Manjula Reddy, Cuc Davis, Jackson Wong, Uma Prabhakar, Cutaneous lymphocyte antigen expression on activated lymphocytes and its association with IL-12R (β1 and β2), IL-2Rα, and CXCR3 Cellular Immunology. ,vol. 236, pp. 131- 139 ,(2005) , 10.1016/J.CELLIMM.2005.08.019
Claire L. Langrish, Brent S. McKenzie, Nicholas J. Wilson, Rene de Waal Malefyt, Robert A. Kastelein, Daniel J. Cua, IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunological Reviews. ,vol. 202, pp. 96- 105 ,(2004) , 10.1111/J.0105-2896.2004.00214.X